News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
376,294 Results
Type
Article (14738)
Company Profile (115)
Press Release (361436)
Multimedia
Podcasts (50)
Webinars (9)
Section
Business (112782)
Career Advice (457)
Deals (18655)
Drug Delivery (41)
Drug Development (31257)
Employer Resources (51)
FDA (8838)
Job Trends (7696)
News (173038)
Policy (12397)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (3)
Academia (1332)
Accelerated approval (10)
Allergies (71)
Alliances (34933)
ALS (42)
Alzheimer's disease (628)
Antibody-drug conjugate (ADC) (179)
Approvals (9042)
Artificial intelligence (444)
Autoimmune disease (61)
Automation (31)
Bankruptcy (131)
Best Places to Work (6520)
BIOSECURE Act (7)
Biosimilars (31)
Biotechnology (85)
Bladder cancer (62)
Brain cancer (27)
Breast cancer (262)
Cancer (2189)
Cardiovascular disease (149)
Career advice (416)
Career pathing (9)
CAR-T (200)
CDC (8)
Cell therapy (489)
Cervical cancer (21)
Clinical research (25870)
Collaboration (1231)
Compensation (230)
Complete response letters (8)
COVID-19 (1223)
CRISPR (85)
C-suite (481)
Cystic fibrosis (60)
Data (2637)
Decentralized trials (1)
Denatured (26)
Depression (43)
Diabetes (211)
Diagnostics (5145)
Digital health (36)
Diversity (7)
Diversity, equity & inclusion (9)
Drug discovery (163)
Drug pricing (19)
Drug shortages (4)
Duchenne muscular dystrophy (86)
Earnings (40524)
Editorial (9)
Employer branding (8)
Employer resources (45)
Events (53410)
Executive appointments (549)
FDA (10442)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (5)
Frontotemporal dementia (8)
Funding (897)
Gene editing (171)
Generative AI (38)
Gene therapy (345)
GLP-1 (302)
Government (1278)
Grass and pollen (3)
Guidances (220)
Healthcare (9917)
HIV (23)
Huntington's disease (13)
IgA nephropathy (26)
Immunology and inflammation (68)
Immuno-oncology (19)
Indications (50)
Infectious disease (1364)
Inflammatory bowel disease (81)
Inflation Reduction Act (5)
Influenza (73)
Intellectual property (151)
Interviews (52)
IPO (8060)
IRA (10)
Job creations (1438)
Job search strategy (363)
JPM (20)
Kidney cancer (6)
Labor market (24)
Layoffs (131)
Leadership (7)
Legal (2534)
Liver cancer (43)
Longevity (6)
Lung cancer (245)
Lymphoma (171)
Machine learning (34)
Management (18)
Manufacturing (524)
MASH (36)
Medical device (11842)
Medtech (11891)
Mergers & acquisitions (11229)
Metabolic disorders (399)
Multiple sclerosis (62)
NASH (3)
Neurodegenerative disease (120)
Neuropsychiatric disorders (19)
Neuroscience (1082)
NextGen: Class of 2026 (3537)
Non-profit (1533)
Now hiring (15)
Obesity (139)
Opinion (97)
Ovarian cancer (92)
Pain (105)
Pancreatic cancer (101)
Parkinson's disease (118)
Partnered (20)
Patents (301)
Patient recruitment (243)
Peanut (31)
People (33675)
Pharmaceutical (18)
Pharmacy benefit managers (3)
Phase 1 (9519)
Phase 2 (11616)
Phase 3 (7552)
Pipeline (2546)
Policy (59)
Postmarket research (502)
Preclinical (4282)
Press Release (66)
Prostate cancer (96)
Psychedelics (6)
Radiopharmaceuticals (177)
Rare diseases (299)
Real estate (3398)
Recruiting (22)
Regulatory (10374)
Reports (20)
Research institute (1300)
Resumes & cover letters (69)
Rett syndrome (21)
RNA editing (9)
RSV (40)
Schizophrenia (32)
Series A (162)
Series B (109)
Service/supplier (6)
Sickle cell disease (32)
Special edition (1)
Spinal muscular atrophy (60)
Sponsored (20)
Startups (2528)
State (2)
Stomach cancer (2)
Supply chain (48)
Tariffs (10)
The Weekly (23)
Vaccines (496)
Venture capital (43)
Weight loss (49)
Women's health (45)
Worklife (2)
Date
Last 7 days (274)
Last 30 days (1063)
Last 365 days (14649)
2026 (1396)
2025 (15031)
2024 (18706)
2023 (22097)
2022 (30814)
2021 (32512)
2020 (30537)
2019 (25793)
2018 (19458)
2017 (18872)
2016 (17761)
2015 (20561)
2014 (15177)
2013 (12742)
2012 (13781)
2011 (14066)
2010 (12826)
Location
Africa (325)
Alabama (69)
Alaska (6)
Arizona (178)
Arkansas (10)
Asia (24891)
Australia (4316)
California (5290)
Canada (1668)
China (547)
Colorado (284)
Connecticut (235)
Delaware (107)
Europe (50935)
Florida (906)
Georgia (219)
Hawaii (2)
Idaho (33)
Illinois (471)
India (33)
Indiana (263)
Iowa (8)
Japan (271)
Kansas (101)
Kentucky (15)
Louisiana (18)
Maine (22)
Maryland (718)
Massachusetts (3540)
Michigan (274)
Minnesota (407)
Mississippi (4)
Missouri (98)
Montana (27)
Nebraska (15)
Nevada (51)
New Hampshire (83)
New Jersey (1561)
New Mexico (18)
New York (1418)
North Carolina (758)
North Dakota (9)
Northern California (2241)
Ohio (169)
Oklahoma (16)
Oregon (24)
Pennsylvania (1010)
Puerto Rico (19)
Rhode Island (34)
South America (512)
South Carolina (60)
South Dakota (1)
Southern California (2267)
Tennessee (103)
Texas (876)
United States (19712)
Utah (193)
Vermont (1)
Virginia (90)
Washington D.C. (18)
Washington State (502)
West Virginia (3)
Wisconsin (87)
Wyoming (1)
376,294 Results for "nexalin technology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
November 14, 2025
·
4 min read
Press Releases
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
February 2, 2026
·
6 min read
Press Releases
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
October 10, 2025
·
1 min read
Press Releases
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
December 3, 2025
·
5 min read
Press Releases
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
November 6, 2025
·
5 min read
Press Releases
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
August 4, 2025
·
4 min read
Press Releases
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
October 31, 2025
·
3 min read
Press Releases
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
September 26, 2025
·
5 min read
Press Releases
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
October 9, 2025
·
5 min read
Press Releases
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
August 26, 2025
·
3 min read
1 of 37,630
Next
